Q-omics provides the consensus-scored BTBD19 profile across patient tissues and cancer cell-line models. BTBD19 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BTBD19 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, BTBD19 RNA expression shows 19,697 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where BTBD19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD19 survival associations across molecular data types. BTBD19 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD19 RNA expression–survival associations across cancer types. High BTBD19 expression shows unfavorable associations in KIRC, LGG, STAD and BLCA, but favorable associations in UCEC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BTBD19 RNA expression.
This table summarizes BTBD19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BTBD19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD19 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRP, KIRC, COAD and HNSC. The KIRP box plot shows higher BTBD19 RNA expression in tumor versus normal tissue (log2 FC = +1.271, t-test p < 0.001).
This table shows molecular features associated with BTBD19 in patient tissues and cancer cell lines. In patient samples, BTBD19 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BTBD19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
